Not independent
Tenure on this board
4.9 yrs
Meeting calendar
TNGX · Annual meeting · Thursday, June 4, 2026
Tango Therapeutics Inc
3 nominees · 3 ballot items.
Elect three Class II directors; ratify PricewaterhouseCoopers LLP as independent auditors for 2026; and approve, on a non-binding advisory basis, the compensation of named executive officers.
Market cap
$4.1B
1Y TSR
+379.7%
Board grade
B
Record date
Apr 7, 2026
Filing
DEF 14A
Meeting concluded · Jun 4, 2026
Follow how the vote landed and what changed on Tango Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Class II Directors
ManagementBoard: FORElect three Class II directors—Malte Peters, M.D.; Kanishka Pothula; and Mace Rothenberg, M.D.—each to serve a three-year term expiring in 2029.
- 2
Ratification of the Appointment of the Independent Registered Public Accounting Firm
ManagementBoard: FORRatify PricewaterhouseCoopers LLP as Tango’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
More detail
This proposal asks shareholders to ratify PwC as the independent auditor for fiscal 2026. Management and the audit committee present it as routine governance: PwC has served since 2017, the audit committee annually reviews its independence and performance, and ratification provides stockholder endorsement though the committee retains discretion to change auditors if warranted. The board recommends a "FOR" vote because the audit committee believes PwC is qualified and independence reviews have not identified impairing relationships; ratification is a standard practice that facilitates the timely completion of the audit and reflects continuity in audit expertise and institutional knowledge.
- 3
Non-Binding Advisory Vote to Approve Named Executive Officer Compensation (Say-on-Pay
ManagementBoard: FORA non-binding advisory vote to approve the compensation of the named executive officers as disclosed in the proxy statement.
More detail
This is a non-binding advisory vote asking shareholders to approve the overall executive compensation as disclosed. Management seeks endorsement of its pay-for-performance program, which mixes base salary, annual performance-based cash bonuses tied to corporate and individual metrics, and long-term equity (options and RSUs) that vest over multiple years to align incentives with shareholder value and retention. The company explains compensation governance, peer benchmarking, independent compensation advisor use, clawback policy, and other safeguards. The board recommends a "FOR" vote and will consider the advisory outcome in future compensation decisions; however, the vote is not binding and the board retains discretion.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
2.5 yrs
Independent
Tenure on this board
4.9 yrs
Also a director at
Surrozen Inc (SRZN)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | 9.2% | 13,300,620 | $278M |
| 2 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 8.9% | 12,809,485 | $268M |
| 3 | Boxer Capital Management, LLC | 7.5% | 10,876,219 | $228M |
| 4 | TCG Crossover Management, LLC | 7.3% | 10,531,071 | $220M |
| 5 | FARALLON CAPITAL MANAGEMENT LLCActivist | 6.3% | 9,097,411 | $190M |
| 6 | Woodline Partners LP | 5.5% | 8,000,013 | $167M |
| 7 | Nextech Invest, Ltd. | 5.0% | 7,266,081 | $152M |
| 8 | FMR LLC | 4.7% | 6,759,598 | $141M |
| 9 | TRV GP IV, LLC | 4.4% | 6,374,574 | $133M |
| 10 | Siren, L.L.C. | 3.9% | 5,657,105 | $118M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Tango Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$3.9B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.6B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.5B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.7B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Reference
Frequently asked questions
- When is the Tango Therapeutics Inc 2026 annual meeting?
- Tango Therapeutics Inc (TNGX) holds its 2026 annual shareholder meeting on Thursday, June 4, 2026.
- What is the record date for the Tango Therapeutics Inc 2026 meeting?
- The record date for the Tango Therapeutics Inc 2026 meeting is Tuesday, April 7, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Tango Therapeutics Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Tango Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Tango Therapeutics Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Tango Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.